Navigation Links
Folate and vitamin B12 reduce disabling schizophrenia symptoms in some patients
Date:3/6/2013

Adding the dietary supplements folate and vitamin B12 to treatment with antipsychotic medication improved a core symptom component of schizophrenia in a study of more than 100 patients. The study focused on negative symptoms of schizophrenia which include apathy, social withdrawal, and a lack of emotional expressiveness. While the level of improvement across all participants was modest, results were more significant in individuals carrying specific variants in genes involved with folate metabolism. The report from a team based at Massachusetts General Hospital (MGH) will appear in the journal JAMA Psychiatry (formerly Archives of General Psychiatry) and has been issued online.

"The symptoms of schizophrenia are complex, and antipsychotic medications provide no relief for some of the most disabling parts of the illness. These include negative symptoms, which can be particularly devastating," says Joshua Roffman, MD, MMSc, of the MGH Department of Psychiatry, corresponding author of the JAMA Psychiatry paper. "Our finding that folate plus vitamin B12 supplementation can improve negative symptoms opens a new potential avenue for treatment of schizophrenia. Because treatment effects differed based on which genetic variants were present in each participant, the results also support a personalized medical approach to treating schizophrenia."

An essential nutrient, folate (or folic acid) is required for the synthesis of DNA and neurotransmitters and plays a role in the control of gene expression. Adequate folate intake during pregnancy can reduce the risk of birth defects in particular neural tube defects and studies have suggested that folate deficiency during pregnancy significantly increases the risk of schizophrenia among offspring. Earlier research by members of the MGH-based team associated low blood folate levels with more severe negative symptoms among patients with schizophrenia.

The current study was designed specifically to investigate whether supplementation with folate and B12 which can magnify the effects of folate reduced negative symptoms of schizophrenia. A 2011 pilot study found symptom improvement only among patients carrying a variant in a folate-pathway gene called MTHFR that reduced the gene's activity. To get a clearer picture of folate's effect on negative symptoms, the current study enrolled 140 patients with schizophrenia at community mental health centers in Boston, Rochester, N.Y., and Grand Rapids, Mich.

Participants were all taking antipsychotic medications which have been shown to alleviate positive symptoms, such as hallucinations and delusions, but not negative symptoms and were randomized to receive daily doses of either folate and vitamin B12 or a placebo for 16 weeks. Every two weeks their medical and psychiatric status was evaluated, using standard symptom assessment tools along with measurements of blood levels of folate and homocysteine, an amino acid that tends to rise when folate levels drop. Nutritional information was compiled to account for differences in dietary intake of the nutrients. Participants' blood samples were analyzed to determine the variants they carried of MTHFR and three other folate-pathway genes previously associated with the severity of negative symptoms of schizophrenia.

Among all 140 participants in the study protocol, those receiving folate and vitamin B12 showed improvement in negative symptoms, but the degree of improvement was not statistically significant compared with the placebo group. But when the analysis accounted for the variants in the genes of interest, intake of the two nutrients did provide significant improvement in negative symptoms, chiefly reflecting the effects of specific variants in MTHFR and in a gene called FOLH1. Variants in the other two genes studied did not appear to have an effect on treatment outcome.

While a low-functioning variant in FOLH1 had been associated with more severe negative symptoms in previous research, in this study it was the high-functioning FOLH1 variant that predicted a better treatment outcome. Measurement of participants' blood folate levels throughout the study provided an explanation for this unexpected finding. Those with the low-functioning FOLH1 variant started the trial with substantially lower folate levels, suggesting a problem with folate absorption. Although supplementation enabled their blood folate levels to eventually catch up with those of participants with the high-functioning variant, it was probably too late to produce symptom improvement during the 16-week trial period.

"For participants who did show a benefit, it took the full 16 weeks of treatment for that benefit to appear," Roffman explains. "While we don't know why this is the case, changes in gene expression which take time are a likely explanation. Folate plays a critical role in DNA methylation, which regulates gene expression, so it's plausible that its effects on negative symptoms act through gene expression changes. Participants with the low-functioning FOLH1 variant might eventually show a benefit of folate supplementation if treated for a longer period of time, but that needs to be investigated in future studies."

He adds that, while the benefits of supplementation for the overall group were modest, the lack of effective treatment for negative symptoms and the safety of folate and vitamin B12 supplementation support the need for larger-scale trials. In addition, the impact of genotype on this study's results suggests the need to investigate the role of folate pathway variants in conditions such as dementia and cardiovascular disease, in which low folate appears to increase risk but supplementation trials have had inconclusive results.

"We are now conducting a clinical trial of 1-methylfolate, which bypasses some of these folate-pathway enzymes and might have greater efficiency among individuals with low-functioning variants," explains Roffman, an assistant professor of Psychiatry at Harvard Medical School. "Understanding more about the basic neural mechanisms of folate in patients with schizophrenia could help us generate more targeted and effective interventions to reduce and possibly even prevent symptoms."


'/>"/>

Contact: Kristen Stanton
kstanton3@partners.org
617-643-3907
Massachusetts General Hospital
Source:Eurekalert

Related biology news :

1. Supplement use predicts folate status in Canadian women
2. Organic tomatoes accumulate more vitamin C, sugars than conventionally grown fruit
3. Vitamin C is beneficial against the common cold
4. African-American, Caucasian women should take identical vitamin D doses
5. Quantum dots deliver Vitamin D to tumors for possible inflammatory breast cancer treatment
6. Vitamin D holds promise in battling a deadly breast cancer, Saint Louis University researchers say
7. Supplements and cows milk play biggest roles in determining vitamin D levels in children
8. Low vitamin D levels in pregnancy associated with lower birth weights, pitt research finds
9. New review associates vitamin D with lower rates of tooth decay
10. Newly discovered effects of vitamin D on cancer
11. Fetus suffers when mother lacks vitamin C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Republic , February 8, 2016 ... global payment platform which presents innovation for clients, ... Authentication feature called VoiceKey. --> Worldcore ... which presents innovation for clients, comfort and unbeatable ... VoiceKey. --> Worldcore is ...
(Date:2/3/2016)... -- --> --> ... Identification System Market by Component (Hardware and Software), Search ... Government, Healthcare, and Transportation) and Geography - Global Forecast ... to be worth USD 8.49 Billion by 2020 at ... The transformation and technology evolution from the manual process ...
(Date:2/2/2016)... , Feb. 2, 2016 This BCC ... bioinformatic market by reviewing the recent advances in ... that drive the field forward. Includes forecast through ... Identify the challenges and opportunities that exist in ... software solution developers, as well as IT and ...
Breaking Biology News(10 mins):
(Date:2/10/2016)... York, and New York, New York (PRWEB) , ... ... ... Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) today announced that it has ... develop new vaccines and immunotherapies for infectious diseases and cancer. , ...
(Date:2/10/2016)... BOSTON , Feb. 10, 2016  Matchbook, ... sourcing for fast growing biotech companies, announced today ... Senior Procurement Strategic Advisor. Jim brings nearly 25 ... sourcing and procurement, having spent nearly two decades ... Supply Chain/Logistics and Procurement at Genzyme and, most ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... LATHAM, NEW ... at the SPIE Photonics West conference in San Francisco’s Moscone Center from ... in the same venue. , These latest InGaAs PIN diode standard packages feature ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... available on Microsoft Azure. On Azure, Arvados provides capabilities for managing and processing ... demand for Microsoft Azure from major institutions collecting and analyzing genomic data,” said ...
Breaking Biology Technology: